Named on one round in the feed.
Since 2026-06-24
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Ollin Biosciences Ollin sells innovative therapies targeting serious eye diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $330M | 2026-06-24 | [ PART ] |